Many patients presenting to hospital emergency departments for the evaluation of chest pain have symptoms and electrocar-
diograms that are both nonspecific and inconclusive [1, 2] .
During the past 30 years, the development of sophisticated serum assays for specific proteins has greatly assisted in the diagnosis of both acute and subtle manifestations of coronary artery disease. Despite the technological advances in diagnostic laboratory medicine and noninvasive cardiac imaging, however, the etiology of acute chest pain remains a difficult diagnostic problem [3] .
Currently, the diagnosis of acute myocardial infarction (AMJ), as defined by the World Health Organization (WHO), is based on the presence of any two of the following in the patient:
clinicalfeatures and chest pain; electrocardiographic changes;
and abnormal values for creatine kinase (CK) and the MB isoenzyme of creatine kinase (CK-MB) [4] . Although the temporal changes in the serum concentrations of CK-MB are relatively specific for an AMI, the lack of complete tissue specificityof this enzyme often results in a misdiagnosis (falsely positive) of myocardial infarction [5] . Additionally, the reported lack of diagnostic sensitivity of this marker early in the course of an Alvll precludes its use as a means of early diagnosis [6] . Given the aggressive surgical and medical interventions associated with an evolving AMI, and the cost of hospitalization of non-AMI patients with acute chest pain syndrome until the presence of myocardial damage has been excluded [2, 7] , the need for an accurate and rapid diagnosis of AMI is crucial for the proper, effective, and efficient management of these patients. As a result, several biochemical markers have been proposed as potential supplements to the measurement of CK-MB to assist in the diagnosis of AMI. Three such proteins are myoglobin, the tissue-associatedisoform of CK-MB (CK-MB2), and troponin. Myoglobin is found in the cytosolic fraction of both cardiac and skeletal muscle tissue. In the absence of skeletal muscle trauma or other factors associated with non-cardiac-related release of myoglobin [8, 9] , rapid and pronounced increases in myoglobin serum concentrations have been used as an early marker for AMI. Several investigators have reported the rapid increase of serum myoglobin after AMI, with peak values occurring between 6 and 9 h after the occlusion of a coronary artery [10, 11] . CK-MB exists in serum as a polymorphic mixture of isoforms [12, 13] produced by the catabolism of CK-MB2, the tissue form of CK-MB [14] .Puleo et al. have proposed [15] that an assay of CK-MB isoforms sufficiently sensitive to detect diagnostic changes in the CK isoform composition in serum when concentrations of CK-MB are normal would clearly be of clinical utility. Currently, all of the reported methods for separating and quantifying the isoforms of CK-MB [15] [16] [17] [18] [19] [20] are based on the analysis of the activity of CK-MB2 and (or) CK-MB 1 and reportedly lack either the low-end sensitivity or the specificity [21, 22] TroponinT assay. Serum u-oponin T concentrations were determined by using the CardiAC T ELISA on the ES 300#{174} analyzer (Boehringer Mannheim, Indianapolis, IN). The performance of this method, relative to its high specificity for cardiac injury [24] , has been reported by Ravkilde et al. [25] . The upper limit of normal for this assay was 0.2 jigfL in a healthy adult population.
CK-MB2 assay.
We determined serum concentrations of CK-MB2 as previously described [23] . The upper limit of normal for the CK-MB2 assay was determined to be 3 pgfL of CK-MB and 70% as CK-MB2 in both hospitalized noncardiac patients and healthy ambulatory adults.
Effect of storagetemperature on analyte stabilily. Six patients' samples, drawn into siliconized glass blood-collection tubes, were analyzed for initial (0 h) CK-MB2 concentration. The samples were aliquoted; stored at 4 #{176}C, room temperature (25 #{176}C), and 37 #{176}C; and reanalyzed for CK-MB2 concentration after 6 h of storage. All values obtained represent the mean of three determinations.
STATISTICS
The results of serial CK-MB and CK-MB2 determinations were correlated with the eventual clinical diagnosis. The sensitivity (true-positive rate in patients with infarction) and specificity (true-negative rate in patients without infarction) were determined for both assays at each of the postpresentation time points analyzed.
A serum marker was judged to be positive if its concentration in any of the four specimens was greater than the cutoff limit. The positive predictive value was defined as the number of true-positive results divided by the total number of positive results, and the negative predictive value was defined as the number of true-negative results divided by the total number of negative results. The 95% confidence intervals for the population proportions were calculated from the sample proportions by using the appropriate upper-tail probability [26] . A paired t-test was used to compare numerical data obtained from the CK-MB2 stability study.
Results

STABILITY
OF CK-MB2
We investigated the in vitro stability of CK-MB2 in serum samples stored at various temperatures.
As shown in [27] , patients diagnosed with unstable angina, angina, or noncardiac chest pain were examined for independent evidence of ischemic myocardial damage by a commercially available troponin T assay [25, [28] [29] [30] . Serum concentrations of troponin T exceeded the reference interval (>0.2 jig/L) in one patient diagnosed with noncardiac chest pain, and in four patients diagnosed with unstable angina. In two of these patients (one diagnosed with noncardiac chest pain and one with unstable angina), CK-MB2, CK-MB, and myoglobin were also increased.
The remaining three patients diagnosed with unstable angina exhibited abnormal increases of both CK-MB2 and myoglobin.
Thus, given the high probability that myocardial damage was present in these patients, the relative sensitivities, specificities, and predictive values for the diagnosis of potential myocardial injury were as shown in Tables 4 and 5 .
Discussion
STABILITY OF CK-MBZ
The relative stability of the isoforms of CK remains controversial; it is not clear how quickly degradation occurs either in vivo or in vitro. Several investigators have indicated the need for preservatives to maintain the integrity of isoform activity. Nohara et al. [31] added ethylene glycol-bis (13-aminoethyl ether) at a final concentration of 7.5-10 mmollL and mercaptoethanol at 5 mmolJL to the sample to maintain activity. Chapelle [32] collected samples for isoform analysis in tubes containing disodium EDTA, 5 mmollL.
Additionally, Rather, the data suggest that the mass concentration of this isoform is stable for limited times in isolated samples when measured by specific monoclonal antibodies.
CLINICAL EVALUATION
The similar release kinetics of CK-MB2 and CK-MB precludes the use of the isoforms of CK-MB2 as a sensitive marker of myocardial damage early in the course of an AMI. Furthermore, although the diagnostic sensitivity of CK-MB2 may be slightly greater than that of CK-MB for diagnosing an AMI in a small subset of patients, the majority of our patients exhibited abnormal increases of both CK-MB and CK-MB2 at identical times after the onset of chest pain. Thus, determination of the serum concentration of CK-MB2 in all patients with acute chest pain is of limited utility. Additionally, myoglobin was shown to lack sufficient diagnostic specificity. Both CK-MB and myoglobin were highly specific (98-100%) at presentation and 3 h after presentation. In a similar study of 133 patients, Tucker et al. [41] reported the sensitivity, specificity, negative predictive value, and positive predictive value of myoglobin at presentation to be 44%, 96%, 81%, and 82%, respectively.
These values increased to 78%, 94%, 91%, and 83% after 4 h. CK-MB was slightly less sensitive (34% and 63% at presentation and at 4 h) and had a lower negative predictive value (79% at presentation and 87% at 4 h) than myoglobin but was more specific (99% and 100% at presentation and at 4 h) with a higher positive predictive value (88% at presentation and 100% at 4 h). More importantly, in a prospective study of 37 patients with an AM! presenting within 4 h after the onset of chest pain, Mair et al. [42] found that differences in the early sensitivities of myoglobin, CK-MB mass, and CK isoform (activity) ratios were small and of little clinical relevance.
Given the differences in the demographics, the inclusion and exclusion criteria, the diagnoses of the patients in these studies, the analytical methods used, and the relative inaccuracy in the time of onset of chest pain, the results of these studies appear to be in agreement.
Previous investigators have indicated that the isoforms of CK-MB are both more sensitive and more specific than CK-MB for the diagnosis of AMI. Puleo et al. [16] determined the sensitivity of the CK-MB2/CK-MB1 ratio to be 8%, 56%, and 96% at 2, 4, and 6 h after onset of symptoms, respectively, compared with the sensitivity of CK-MB (0%, 23%, and 48% at the same times). Although our results may suggest a minor improvment in the sensitivity of CK-MB2 relative to CK-MB in a small subset of patients with acute chest pain, we did not observe the differences in sensitivity and specificity noted by Puleo et al. This apparent inconsistency may be caused in part by differences between the assay methods used for CK-MB2 and CK-MB. We found the isoform immunochemical mass assay [23] to be equivalent to the activity assay for measuring and quantifying CK-MB2 in patients' sera when present in high concentrations.
Thus, our anti-B subunit capture and anti-(M + lysine) subunit conjugate assay system measures all of the CK-MB isoform associated with the CK-MB2 electrophoretic band. In both assay systems, the exact nature of the B subunit of CK-MB2 relative to the presence or absence of a terminal lysine group is unknown.
However, as was evident in the previously described quantification of CK-MB2 within the normal reference interval [23] , the immunochemical mass assay for CK-MB2 utilized herein is more sensitive than the activity-based assay previously reported by Puleo et al. [16] . This increased sensitivity also does not appear to result from equivalent assays with differentreference ranges, because the upper limit of normal for %CK-MB2 (70%) as determined by the immunochemical assay ismuch higher than that used (CK-MB2/CK-MB1 ratio of 1.5, corresponding to a %CK-MB2 of 60%) in the activity assay. Thus, if the two assay systems were equivalent for measuring low concentrations of CK-MB2, the mass determination would exhibit a lower diagnostic sensitivity than the existing CK-MB2 activity method.
Of equal importance in the comparison of these studies is the nature of the CK-MB assay used. Our results suggest that the differences between the sensitivities of CK-MB2 and CK-MB are substantially less than those reported by Puleo et al. This is probably a direct result of the use of a highly sensitivemass assay for CK-MB in our study rather than the relatively insensitive activity-based method they used. 
